NEW YORK, Sept. 8, 2025 /PRNewswire/ -- Pomerantz LLP announces that a class action lawsuit has been filed against Semler Scientific, Inc. ("Semler" or the "Company") (NASDAQ:SMLR). Such investors are advised to contact Danielle Peyton at newaction@pomlaw.com or 646-581-9980, (or 888.4-POMLAW), toll-free, Ext. 7980. Those who inquire by e-mail are encouraged to include their mailing address, telephone number, and the number of shares purchased.
The class action concerns whether Semler and certain of its officers and/or directors have engaged in securities fraud or other unlawful business practices.
You have until October 28, 2025 to ask the Court to appoint you as Lead Plaintiff for the class if you purchased or otherwise acquired Semler securities during the Class Period. A copy of the Complaint can be obtained at www.pomerantzlaw.com.
[Click here for information about joining the class action]
On February 28, 2025, Semler filed its annual report for full year 2024 and disclosed that "there is a risk that [U.S. Department of Justice ('DOJ')] will file a complaint or complaint in intervention in a civil False Claims Act lawsuit seeking damages for tests performed using our device[.]" The Company also revealed it had received an initial civil investigative demand from the DOJ in July 2017 regarding Semler's claims for reimbursement related to its peripheral artery disease QuantaFlo device. The Company further stated that it had participated in settlement discussions with the DOJ in February 2025, which were unsuccessful.
On this news, Semler's stock price fell $4.03 per share, or 9.4%, to close at $38.89 per share on March 3, 2025.
Then, on April 15, 2025, Semler announced that it had reached an agreement with the DOJ "in principle on payment of $29.75 million to settle all claims."
On this news, Semler's stock price fell $3.40 per share, or 9.88%, to close at $31.00 per share on April 16, 2025.
Pomerantz LLP, with offices in New York, Chicago, Los Angeles, London, Paris, and Tel Aviv, is acknowledged as one of the premier firms in the areas of corporate, securities, and antitrust class litigation. Founded by the late Abraham L. Pomerantz, known as the dean of the class action bar, Pomerantz pioneered the field of securities class actions. Today, more than 85 years later, Pomerantz continues in the tradition he established, fighting for the rights of the victims of securities fraud, breaches of fiduciary duty, and corporate misconduct. The Firm has recovered numerous multimillion-dollar damages awards on behalf of class members. See www.pomlaw.com.
Attorney advertising. Prior results do not guarantee similar outcomes.
CONTACT:
Danielle Peyton
Pomerantz LLP
dpeyton@pomlaw.com
646-581-9980 ext. 7980
View original content to download multimedia:https://www.prnewswire.com/news-releases/investor-alert-pomerantz-law-firm-reminds-investors-with-losses-on-their-investment-in-semler-scientific-inc-of-class-action-lawsuit-and-upcoming-deadlines---smlr-302549480.html
SOURCE Pomerantz LLP
